Guficol Plus 2MIU Injection contains Colistimethate Sodium equivalent to 2 Million International Units (IU) per dose, a potent polymyxin antibiotic used primarily for the treatment of severe infections caused by multidrug-resistant Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella species. The mechanism of action involves disruption of the bacterial cell membrane, leading to increased permeability and cell death. This injectable formulation is indicated for systemic infections such as ventilator-associated pneumonia, bloodstream infections, urinary tract infections, and complicated intra-abdominal infections where other antibiotics have failed or are contraindicated. Guficol Plus 2MIU Injection should be administered intravenously under strict medical supervision, with dosage adjusted according to the severity of infection, renal function, and patient response. Due to its nephrotoxic and neurotoxic potential, careful monitoring of renal parameters and neurological status is essential during therapy. It is contraindicated in patients with known hypersensitivity to colistimethate sodium or polymyxins. Use during pregnancy and lactation should be considered only if the potential benefit justifies the potential risk to the fetus or infant. This antibiotic should be reserved for infections where susceptibility testing confirms efficacy to minimize the development of resistance.